Skip to main content

Advertisement

SpringerLink
Log in

Imidazoacridinone antitumor agent C-1311 as a selective mechanism-based inactivator of human cytochrome P450 1A2 and 3A4 isoenzymes

  • Original Research Article
  • Published:
Pharmacological Reports Aims and scope Submit manuscript

Abstract

Background

5-Diethylaminoethylamino-8-hydroxyimidazoacridinone (C-1311), a promising antitumor agent that is also active against autoimmune diseases, was determined to be a selective inhibitor of the cytochrome P450 (CYP) 1A2 and 3A4 isoenzymes. Therefore, C-1311 might modulate the effectiveness of other drugs used in multidrug therapy. The present work aimed to identify the mechanism of the observed C-1311-mediated inactivation of CYP1A2 and CYP3A4.

Methods

The inactivation experiments were performed in vitro using the human recombinant CYP1A2 and CYP3A4 (Bactosomes). CYP isoenzyme activities were determined using the CYP-specific reactions, 7-ethoxycoumarin O-deethylation (CYP1A2) and testosterone 6β-hydroxylation (CYP3A4). The concentrations of CYP-specific substrates and their metabolites formed by CYP isoenzymes were measured by RP-HPLC with UV-Vis detection.

Results

The inhibition of CYPs by C-1311 was time-, concentration- and NADPH-dependent, which suggested a mechanism-based mode of action. Using a 10-fold dilution method and potassium ferricyanide we demonstrated the irreversible nature of the inhibition. In addition, the inhibition was attenuated by the presence of alternate substrates (alternative active site ligands) but not by a nucleophilic trapping agent (glutathione) or a reactive oxygen scavenger (catalase), which further supported a mechanism-based action. Substrate depletion partition ratios of 299 and 985 were calculated for the inactivation of CYP1A2 and CYP3A4, respectively.

Conclusions

Our results indicated that C-1311 is a potent mechanism-based inactivator of CYP1A2 and CYP3A4. This finding provided new insights into the mechanism of C-1311 antitumor action, particularly in relation to potential pharmacokinetic drug-drug interactions between C-1311 and/or its derivatives and the substrates of CYP isoforms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cholody WM, Martelli S, Lukowicz J, Konopa J. 5-[(Aminoalkyl)aminoJimidazo[4,5,1-de]acridin-6-ones as a novel class of antineoplastic agents Synthesis and biological activity. J Med Chem 1990;33:49–52.

    Article  CAS  Google Scholar 

  2. Cholody WM, Horowska B, Paradziej-Lukowicz J, Martelli S, Konopa J. Structure-activity relationship for antineoplastic imidazoacridinones: synthesis and antileukemic activity in vivo. J Med Chem 1996;39:1028–32.

    Article  CAS  Google Scholar 

  3. Skladanowski A, Pilsov SY, Konopa J, Larsen L. Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors. Mol Pharmacol 1996;49:772–80.

    CAS  PubMed  Google Scholar 

  4. Skwarska A, Augustin E, Beffinger M, Wojtczyk A, Konicz S, Laskowska K, et al. Targeting of FLT3-ITD kinase contributes to high selectivity of imidazoacridinone C-1311 against FLT3-activated leukemia cells. Biochem Pharmacol 2015;95:238–52.

    Article  CAS  Google Scholar 

  5. Burger AM, Double J, Konopa J, Bibby MC. Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer. Br J Cancer 1996;74:1369–74.

    Article  CAS  Google Scholar 

  6. Isambert N, Campone M, Bourbouloux E, Drouin M, Major A, Loadman P, et al. Evaluation of the safety of C-1311 administered in a phase I dose-escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumors. Eur J Cancer 2010;46:729–34.

    Article  CAS  Google Scholar 

  7. Capizzi RL, Roman LA, Tjulandin S, Smirnova I, Manikhas A, Paterson JS, et al. Phase II trial of C1311, a novel inhibitor of topoisomerase II in advanced breast cancer. In: 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2008;26(May 20 Suppl):1055.

    Article  Google Scholar 

  8. Smith SC, Havaleshko DM, Moon K, Baras AS, Lee J, Bekiranov S, et al. Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agents. Neoplasia 2011;13:72–80.

    Article  CAS  Google Scholar 

  9. Berger B, Marquardt H, Westendorf J. Pharmacological and toxicological aspects of new imidazoacridinone antitumor agents. Cancer Res 1996;56: 2094–104.

    CAS  PubMed  Google Scholar 

  10. Mazerska Z, Dziegielewski J, Konopa J. Enzymatic activation of a new antitumour drug, 5-diethylaminoethylamino-8-hydroxyimidazoacridinone, C-1311, observed after its intercalation into DNA. Biochem Pharmacol 2001;61:685–94.

    Article  CAS  Google Scholar 

  11. Dziegielewski J, Slusarski B, Konitz A, Skladanowski A, Konopa J. Intercalation of imidazoacridinones to DNA and its relevance to cytotoxic and antitumor activity. Biochem Pharmacol 2002;63:1653–62.

    Article  CAS  Google Scholar 

  12. Wisniewska A, Chrapkowska A, Kot-Wasik A, Konopa J, Mazerska Z. Metabolic transformations of antitumor imidazoacridinone, C-1311, with microsomal fractions of rat and human liver. Acta Biochim Pol 2007;54:831–8.

    Article  CAS  Google Scholar 

  13. Potega A, Dabrowska E, Niemira M, Kot-Wasik A, Ronseaux S, Henderson JC, et al. The imidazoacridinone antitumor drug, C-1311, is metabolized by FMOs but not cytochrome P450s. DMD 2011;39:1423–32.

    Article  CAS  Google Scholar 

  14. Fedejko-Kap B, Bratton SM, Finel M, Radominska-Pandya A, Mazerska Z. Role of human UDP-glucuronosyltransferases in the biotransformation of the triazoloacridinone and imidazoacridinone antitumor agents C-1305 and C-1311: highly selective substrates for UGT1A10. DMD 2012;40:1736–43.

    Article  CAS  Google Scholar 

  15. Hutzler JM, Melton RJ, Rumsey JM, Schnute ME, Locuson CW, Wienkers LC. Inhibitionofcytochrome P450 bypyrimidineimidazole: evidenceforcomplex heme interactions. Chem Res Toxicol 2006;19:1650–9.

    Article  CAS  Google Scholar 

  16. Murray M, Murray K. Mechanism-based inhibition of CYP activities in rat liver by fluoxetine and structurally similar alkylamines. Xenobiotica 2003;10: 973–87.

    Article  Google Scholar 

  17. Kalgutkar AS, Obach RS, Maurer TS. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. Curr Drug Metab 2007;8:407–47.

    Article  CAS  Google Scholar 

  18. Ortiz de Montellano PR. Mechanism-based inactivation ofcytochrome P450: isolation and characterization N-alkyl heme adducts. Methods Enzymol 1991;206:533–40.

    Article  CAS  Google Scholar 

  19. Yamazaki H, Inoue K, Mimura M, Oda Y, Guengerich FP, Shimada T. 7-Ethoxycoumarin O-deethylation catalysed by cytochromes P450 1A2 and 2E1 in human liver microsomes. Biochem Pharmacol 1996;51:313–9.

    Article  CAS  Google Scholar 

  20. Yuan R, Madani S, Wei XX, Reynolds K, Huang SM. Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. DMD 2002;30:1311–9.

    Article  CAS  Google Scholar 

  21. Silverman RB. In: Purich DL, editor. Mechanism-based enzyme inactivation, in Contemporary Enzyme Kinetics and Mechanisms. San Diego, CA: Academic Press; 1996. p. 291–335.

  22. Trunzer M, Faller B, Zimmerlin A. Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS/MS validation. J Med Chem 2009;52:329–35.

    Article  CAS  Google Scholar 

  23. Mazerska Z, Sowinski P, Konopa J. Molecular mechanism of the enzymatic oxidation investigated for imidazoacridinone antitumor drug, C-1311. Biochem Pharmacol 2003;66:1727–36.

    Article  CAS  Google Scholar 

  24. Guengerich FP. Human cytochrome P450 enzymes. In: Ortiz de Montellano, editor. Cytochromes P450. New York: Plenum Press; 1995. p. 473–535.

    Chapter  Google Scholar 

  25. Richter T, Schwab M, Eichelbaum M, Zanger UM. Inhibition of human CYP2B6 by N,N′,N″-triethylenethiophosphoramide is irreversible and mechanism-based. Biochem Pharmacol 2005;69:517–24.

    Article  CAS  Google Scholar 

  26. Liu X, Lu Y, Guan X, Dong B, Chavan H, Wang J, et al. Metabolomics reveals the formation of aldehydes and iminium in gefitinib metabolism. Biochem Pharmacol 2015;97:111–21.

    Article  CAS  Google Scholar 

  27. Foo WY, Tay HY, Chan EC, Lau AJ. Meclizine, a pregnane X receptor agonist, is a direct inhibitor and mechanism-based inactivator ofhuman cytochrome P450 3A. Biochem Pharmacol 2015;97:320–30.

    Article  CAS  Google Scholar 

  28. De Groot MJ, Ekins S. Pharmacophore modeling of cytochromes P450. Adv Drug Deliv Rev 2002;54:367–83.

    Article  Google Scholar 

  29. Ohyama K, Nakajima M, Suzuki M, Shimada N, Yamazaki H, Yokoi T. Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br J Clin Pharmacol 2000;49:244–53.

    Article  CAS  Google Scholar 

  30. Polasek TM, Miners JO. Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants. Br J Clin Pharmacol 2008;65:87–97.

    Article  CAS  Google Scholar 

  31. Wang YH, Jones DR, Hall SD. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. DMD 2004;32:259–66.

    Article  CAS  Google Scholar 

  32. Zhao XJ, Jones DR, Wang YH, Grimm SW, Hall SD. Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Xenobiotica 2002;32:863–78.

    Article  CAS  Google Scholar 

  33. Barbara JE, Kazmi F, Muranjan S, Toren PC, Parkinson A. High-resolution mass spectrometry elucidates metabonate (false metabolite) formation from alkylamine drugs during in vitro metabolite profiling. DMD 2012;40:1966–75.

    Article  CAS  Google Scholar 

  34. Fontana E, Dansette PM, Poli SM. Cytochrome P450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr Drug Metab 2005;6:413–54.

    Article  CAS  Google Scholar 

  35. Locuson CW, Hutzler JM, Tracy TS. Visible spectra of type II cytochrome P450-drug complexes: evidence that incomplete heme coordination is common. DMD 2007;35:614–22.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Technology and Biochemistry, Chemical Faculty, Gdańsk University of Technology, Gdańsk, Poland

    Agnieszka Potęga, Barbara Fedejko-Kap & Zofia Mazerska

Authors
  1. Agnieszka Potęga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barbara Fedejko-Kap
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zofia Mazerska
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Agnieszka Potęga.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Potęga, A., Fedejko-Kap, B. & Mazerska, Z. Imidazoacridinone antitumor agent C-1311 as a selective mechanism-based inactivator of human cytochrome P450 1A2 and 3A4 isoenzymes. Pharmacol. Rep 68, 663–670 (2016). https://doi.org/10.1016/j.pharep.2016.02.003

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1016/j.pharep.2016.02.003

Keywords

Search

Navigation